# Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer

> **NCT03442504** · NA · UNKNOWN · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 57 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** FES PET/CT

## Key facts

- **NCT ID:** NCT03442504
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-15
- **Primary completion:** 2023-01-11
- **Final completion:** 2024-06
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03442504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03442504, "Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03442504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*